Crossref
The Development, Efficacy and Safety Profiles of Bispecific Antibodies for Solid Tumors: Amivantamab for EGFR-mutant NSCLC and Tebentafusp for Uveal Melanoma
Archives of Microbiology & Immunology · 2026 · 10 (2)
DOI: 10.26502/ami.936500236 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Microbiology & Immunology, 2026. Verfasst von Priya Hays.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Hays, P. (2026). The Development, Efficacy and Safety Profiles of Bispecific Antibodies for Solid Tumors: Amivantamab for EGFR-mutant NSCLC and Tebentafusp for Uveal Melanoma. Archives of Microbiology & Immunology, 10(2). https://doi.org/10.26502/ami.936500236
Vancouver
Hays P. The Development, Efficacy and Safety Profiles of Bispecific Antibodies for Solid Tumors: Amivantamab for EGFR-mutant NSCLC and Tebentafusp for Uveal Melanoma. Archives of Microbiology & Immunology. 2026;10(2). doi:10.26502/ami.936500236
BibTeX
@article{Hays2026,
author = {Hays, Priya},
title = {The Development, Efficacy and Safety Profiles of Bispecific Antibodies for Solid Tumors: Amivantamab for EGFR-mutant NSCLC and Tebentafusp for Uveal Melanoma},
journal = {Archives of Microbiology & Immunology},
year = {2026},
volume = {10},
number = {2},
doi = {10.26502/ami.936500236}
}
EUVIMED